A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections

A worldwide estimate of over one million STIs are acquired daily and there is a desperate need for effective preventive as well as therapeutic measures to curtail this global health burden. Vaccines have been the most effective means for the control and potential eradication of infectious diseases;...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Abisola Abisoye-Ogunniyan, Isabella M. Carrano, Dina R. Weilhammer, Sean F. Gilmore, Nicholas O. Fischer, Sukumar Pal, Luis M. de la Maza, Matthew A. Coleman, Amy Rasley
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	STIs vaccines nanoparticles delivery platforms immunogenicity chlamydia Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/0fdef6d619294b57b153251ba39f8257
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:0fdef6d619294b57b153251ba39f8257
record_format	dspace
spelling	oai:doaj.org-article:0fdef6d619294b57b153251ba39f82572021-12-01T08:33:32ZA Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections1663-981210.3389/fphar.2021.768461https://doaj.org/article/0fdef6d619294b57b153251ba39f82572021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fphar.2021.768461/fullhttps://doaj.org/toc/1663-9812A worldwide estimate of over one million STIs are acquired daily and there is a desperate need for effective preventive as well as therapeutic measures to curtail this global health burden. Vaccines have been the most effective means for the control and potential eradication of infectious diseases; however, the development of vaccines against STIs has been a daunting task requiring extensive research for the development of safe and efficacious formulations. Nanoparticle-based vaccines represent a promising platform as they offer benefits such as targeted antigen presentation and delivery, co-localized antigen-adjuvant combinations for enhanced immunogenicity, and can be designed to be biologically inert. Here we discuss promising types of nanoparticles along with outcomes from nanoparticle-based vaccine preclinical studies against non-viral STIs including chlamydia, syphilis, gonorrhea, and recommendations for future nanoparticle-based vaccines against STIs.Abisola Abisoye-OgunniyanIsabella M. CarranoDina R. WeilhammerSean F. GilmoreNicholas O. FischerSukumar PalLuis M. de la MazaMatthew A. ColemanAmy RasleyFrontiers Media S.A.articleSTIsvaccinesnanoparticlesdelivery platformsimmunogenicitychlamydiaTherapeutics. PharmacologyRM1-950ENFrontiers in Pharmacology, Vol 12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	STIs vaccines nanoparticles delivery platforms immunogenicity chlamydia Therapeutics. Pharmacology RM1-950
spellingShingle	STIs vaccines nanoparticles delivery platforms immunogenicity chlamydia Therapeutics. Pharmacology RM1-950 Abisola Abisoye-Ogunniyan Isabella M. Carrano Dina R. Weilhammer Sean F. Gilmore Nicholas O. Fischer Sukumar Pal Luis M. de la Maza Matthew A. Coleman Amy Rasley A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections
description	A worldwide estimate of over one million STIs are acquired daily and there is a desperate need for effective preventive as well as therapeutic measures to curtail this global health burden. Vaccines have been the most effective means for the control and potential eradication of infectious diseases; however, the development of vaccines against STIs has been a daunting task requiring extensive research for the development of safe and efficacious formulations. Nanoparticle-based vaccines represent a promising platform as they offer benefits such as targeted antigen presentation and delivery, co-localized antigen-adjuvant combinations for enhanced immunogenicity, and can be designed to be biologically inert. Here we discuss promising types of nanoparticles along with outcomes from nanoparticle-based vaccine preclinical studies against non-viral STIs including chlamydia, syphilis, gonorrhea, and recommendations for future nanoparticle-based vaccines against STIs.
format	article
author	Abisola Abisoye-Ogunniyan Isabella M. Carrano Dina R. Weilhammer Sean F. Gilmore Nicholas O. Fischer Sukumar Pal Luis M. de la Maza Matthew A. Coleman Amy Rasley
author_facet	Abisola Abisoye-Ogunniyan Isabella M. Carrano Dina R. Weilhammer Sean F. Gilmore Nicholas O. Fischer Sukumar Pal Luis M. de la Maza Matthew A. Coleman Amy Rasley
author_sort	Abisola Abisoye-Ogunniyan
title	A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections
title_short	A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections
title_full	A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections
title_fullStr	A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections
title_full_unstemmed	A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections
title_sort	survey of preclinical studies evaluating nanoparticle-based vaccines against non-viral sexually transmitted infections
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/0fdef6d619294b57b153251ba39f8257
work_keys_str_mv	AT abisolaabisoyeogunniyan asurveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT isabellamcarrano asurveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT dinarweilhammer asurveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT seanfgilmore asurveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT nicholasofischer asurveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT sukumarpal asurveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT luismdelamaza asurveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT matthewacoleman asurveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT amyrasley asurveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT abisolaabisoyeogunniyan surveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT isabellamcarrano surveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT dinarweilhammer surveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT seanfgilmore surveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT nicholasofischer surveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT sukumarpal surveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT luismdelamaza surveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT matthewacoleman surveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections AT amyrasley surveyofpreclinicalstudiesevaluatingnanoparticlebasedvaccinesagainstnonviralsexuallytransmittedinfections
_version_	1718405338117439488

A Survey of Preclinical Studies Evaluating Nanoparticle-Based Vaccines Against Non-Viral Sexually Transmitted Infections

Ejemplares similares